Evidence map›Paper›PMID 41541967›Full record

ArticleCureus2025

Conservative Management of Hemoperitoneum Due to a Ruptured Hemorrhagic Ovarian Cyst in Type 3 von Willebrand Disease.

Hounaida Mahfoud, Rim Laaboudi, Mohamed Elkhorassani, Nabil Elachhab, Samir Bargach

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hounaida MahfoudObstetrics and Gynecology, Ibn Sina University Hospital, Rabat, MAR.
Rim LaaboudiObstetrical Gynecology and High-Risk Pregnancy, Maternity Souissi, Rabat, MAR.
Mohamed ElkhorassaniPediatrics Hematology and Oncology, Ibn Sina University Hospital, Rabat, MAR.
Nabil ElachhabMaternal Critical Care and Anesthesiology, Ibn Sina University Hospital, Rabat, MAR.
Samir BargachObstetrics and Gynecology, Ibn Sina University Hospital, Rabat, MAR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hemoperitoneum secondary to a ruptured hemorrhagic ovarian cyst is usually a benign and self-limiting condition, but in women with type 3 von Willebrand disease (VWD), it may evolve into a severe and potentially life-threatening event due to the inability to achieve spontaneous hemostasis. We report a case of a 30-year-old woman with type 3 VWD who presented with acute pelvic pain and profound anemia. Transvaginal ultrasonography and MRI demonstrated a ruptured hemorrhagic ovarian cyst associated with a large hemoperitoneum. Despite the extent of bleeding, the patient remained hemodynamically stable and was managed conservatively. Treatment consisted of von Willebrand factor replacement, blood transfusion, analgesia, and close clinical and radiological monitoring. Her condition improved progressively, with normalization of hemoglobin levels, resolution of symptoms, and significant regression of the hemoperitoneum on follow-up imaging. No surgical intervention was required. Managing ovarian cyst rupture in severe VMD is particularly challenging, as surgical intervention carries substantial hemorrhagic risk. Conservative management, when supported by adequate hemostatic therapy, can be both safe and effective, preserving ovarian function and reducing perioperative morbidity. This case underscores the importance of individualized, multidisciplinary care to optimize management strategies in women with severe bleeding disorders.

Indexed as

conservative managementhemoperitoneumruptured hemorrhagic cystvon willebrand diseasevon willebrand factor replacement

Identifiers

PMID41541967
PMCPMC12800711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.